Facet joint–mediated pain remains a common and often challenging contributor to chronic axial low back pain, accounting for an estimated 15–45% of cases in interventional pain practices. During a recent APEX Biologix educational webinar, Mohamed Osman, MD, anesthesiologist and pain medicine physician, delivered an in-depth clinical review of modern strategies for diagnosing and managing facet joint pain, examining how traditional interventions compare with emerging orthobiologic approaches.
The educational session focused on evolving treatment paradigms, shifting from repeated symptom suppression toward strategies aimed at improving joint health, biomechanics, and long-term functional outcomes.
Facet joints are paired structures located on the posterior aspect of each spinal level and are classified as true synovial joints. The articular surfaces of the joint are lined with hyaline cartilage and enclosed within a synovial capsule, while sensory transmission is carried through the medial branch nerves of the dorsal rami. Each facet joint receives dual sensory innervation, with medial branches from the level above and the level below the joint contributing to its nerve supply, an important consideration when diagnostic or therapeutic interventions are performed.
Importantly, facet joint pain is rarely an isolated pathology. Degenerative changes in the intervertebral disc can shift axial loading posteriorly, increasing mechanical stress on the facet joints, a concept often described within the functional spinal unit framework. Over time, this altered biomechanics contributes to cartilage degeneration, inflammatory signaling, and progressive joint dysfunction.
Accurate diagnosis remains central to appropriate treatment selection. While history, physical examination, and imaging play important roles, the gold standard for diagnosing facet-mediated pain continues to be comparative diagnostic medial branch blocks.
Consensus guidelines support the use of two diagnostic blocks with different local anesthetics, requiring approximately 80% pain relief with each block to confirm a facetogenic pain source. This step is critical before pursuing either conventional or biologic interventions.
Corticosteroids exert potent anti-inflammatory effects by inhibiting phospholipase A2, often providing short-term symptom relief. However, evidence suggests that benefits typically diminish within several months, and repeated intra-articular steroid exposure has been associated with chondrotoxic effects, potentially accelerating cartilage degeneration over time.
Radiofrequency ablation of the medial branch nerves has long been considered a standard treatment for facet joint pain. Studies demonstrate meaningful pain relief and functional improvement for many patients, often lasting 6–12 months. However, RFA primarily targets pain transmission rather than joint health and may be associated with secondary effects such as multifidus muscle denervation.
Growing interest in orthobiologics reflects a broader shift toward addressing the biologic environment of the joint, rather than focusing solely on pain suppression.
PRP involves concentrating platelets from autologous blood to deliver growth factors, cytokines, and signaling molecules that may support angiogenesis, matrix synthesis, and modulation of synovial inflammation.
Clinical evidence comparing PRP to corticosteroids for lumbar facet pain suggests:
▪️Steroids may provide a quicker onset of symptom reliefLeukocyte-poor PRP is often favored for intra-articular applications due to its lower pro-inflammatory profile.
BMAC introduces mesenchymal stem cells and anti-inflammatory mediators, including interleukin-1 receptor antagonist (IL-1ra), which may help modulate inflammatory cascades within degenerative joints.
Emerging clinical data, including early-phase trials, have demonstrated improvements in pain scores, functional outcomes, and imaging findings in select patient populations, without serious adverse events. BMAC is often considered for patients with more advanced degenerative changes.
While the orthobiologic literature continues to expand, variability in study outcomes highlights the importance of:
▪️Standardizing PRP and BMAC preparation methodsCurrent guideline assessments reflect limited but growing evidence, with expert consensus supporting orthobiologic consideration in appropriately selected patients who have exhausted conservative options or are poor candidates for conventional procedures.
Rather than viewing conventional and biologic interventions as mutually exclusive, the discussion emphasized thoughtful sequencing and combination strategies, guided by patient goals, symptom severity, and timing considerations.
Ultimately, clinicians are encouraged to frame treatment conversations around improving joint health, biomechanics, and long-term function, rather than focusing exclusively on short-term symptom control.
As research continues to evolve, orthobiologics may play an increasingly prominent role in the management of facet joint pathology. Ongoing data collection, improved standardization, and clinician education will be key to refining protocols and identifying ideal candidates.
The guiding principle remains clear:
Treat the tissue not just the signal.
Clinicians can access the recorded, on demand webinar by clicking here: Modern Management of Facet Joint Pain or visiting the APEX Biologix Resource Library, a registration-only platform built exclusively for healthcare professionals.
Clinicians interested in hands-on training, procedural education, and practice implementation strategies can explore the upcoming XCELL RISE - Interventional Pain event hosted at the XCELL Learning Center located in Clearwater, Florida. XCELL RISE – Interventional Pain is a purpose-built educational experience designed for pain physicians integrating biologics into spine and musculoskeletal interventional practices.
Manchikanti L. et al., Comprehensive Evidence-Based Guidelines for Regenerative Therapies in the Management of Chronic Low Back Pain: 2025 Update from ASIPP, Pain Physician (2025).
Cohen S.P. et al., Consensus Practice Guidelines on Interventions for Lumbar Facet Joint Pain from a Multispecialty, International Working Group, Reg’l Anesthesia & Pain Med. (2020).
Kreiner D.S. et al., North American Spine Society (NASS) Guidelines for Diagnosis and Treatment of Low Back Pain, Spine J. (2020).
Manchikanti L. et al., Comprehensive Evidence-Based Guidelines for Facet Joint Interventions in the Management of Chronic Spinal Pain, Pain Physician (2020).
Wu J. et al., A Prospective Study Comparing Platelet-Rich Plasma and Local Anesthetic/Corticosteroid Injection in the Treatment of Lumbar Facet Joint Syndrome, Pain Pract. (2017).
Sanapati J. et al., Do Regenerative Medicine Therapies Provide Long-Term Relief in Chronic Low Back Pain: A Systematic Review and Meta-Analysis, Pain Physician (2018).
Dulic O. et al., Bone Marrow Aspirate Concentrate Versus Platelet-Rich Plasma or Hyaluronic Acid for the Treatment of Knee Osteoarthritis, Medicina (2021).
Patel A. et al., Platelet-Rich Plasma in the Treatment of Facet-Mediated Low Back Pain: A Comprehensive Review, Orthopedic Reviews (2022).
Navani A. et al., Responsible, Safe, and Effective Use of Biologics in the Management of Low Back Pain: ASIPP Guidelines, Pain Physician (2019).
Yilmaz A., Kucukbingoz C., Comparative Outcomes and Safety of Radiofrequency Ablation and Cryoablation for Lumbar Facet Joint Degeneration, J. Clinical Med. (2025).
Geoffroy M. et al., Platelet-Rich Plasma Versus Corticosteroids in Facet Joint Syndrome: A Controlled, Randomized, Double-Blind Study, Jt. Bone Spine (2025).
Dreyfuss P. et al., Efficacy and Validity of Radiofrequency Neurotomy for Chronic Lumbar Zygapophysial Joint Pain, Spine (2000).
Schneider B.J. et al., The Effectiveness of Intradiscal Biologic Treatments for Discogenic Low Back Pain: A Systematic Review, Spine J. (2022).